Melinda Dunlap, MD
Hematology & Oncology · Tulsa, OKNPI 1609096668
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,346 of the $2,668 with a category attached, or 87.9%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $861, 2.5 times the $340 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 118 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$558
- Pfizer$299
- Daiichi Sankyo Inc.$269
- Gilead$265
- Novartis$172
- Sanofi$110
- plus $995 from 28 others
Across 4 payments — averaging $42,752 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$168K
- Bristol Myers Squibb$3K
What the payments were for
- Food & beverage$2,34688%
- Education$32212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $558 |
| Pfizer | 23 | $299 |
| Daiichi Sankyo Inc. | 7 | $269 |
| Gilead | 4 | $265 |
| Novartis | 9 | $172 |
| Sanofi | 5 | $110 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| AbbVie | 4 | $88 |
| Johnson & Johnson | 4 | $87 |
| Janssen Scientific Affairs, LLC | 1 | $77 |
| Seagen Inc. | 4 | $68 |
| AVEO Pharmaceuticals, Inc. | 2 | $50 |
| Beigene USA, Inc. | 2 | $46 |
| Bristol Myers Squibb | 3 | $42 |
| GSK | 2 | $36 |
| Geron Corporation | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Merck | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Eisai Inc. | 2 | $29 |
| Beone Medicines USA, Inc. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Exelixis Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Amgen | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Intuitive Surgical | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,668 in reported general payments places this provider in the 50th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 57 | $915,682 |
| ImbruvicaIbrutinib | 54 | $868,322 |
| CalquenceAcalabrutinib Maleate | 41 | $610,684 |
| IbrancePalbociclib | 22 | $345,203 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $288,260 |
| TasignaNilotinib Hcl | 11 | $210,004 |
| PromactaEltrombopag Olamine | 19 | $191,618 |
| VenclextaVenetoclax | 22 | $184,178 |
| XtandiEnzalutamide | 13 | $182,526 |
| Imatinib Mesylate | 34 | $38,393 |
| EliquisApixaban | 49 | $33,233 |
| XareltoRivaroxaban | 24 | $18,097 |
| Anastrozole | 346 | $5,141 |
| Exemestane | 34 | $3,044 |
| Tamoxifen Citrate | 128 | $2,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $42 | $915,68257 claims |
| AstraZenecaCalquence | $558 | $610,68441 claims |
| NovartisTasigna, Promacta | $172 | $401,62330 claims |
| PfizerIbrance, Eliquis | $299 | $378,43571 claims |
| GSKOjjaara | $36 | $288,26011 claims |
| AbbVieVenclexta | $88 | $184,17822 claims |
| Astellas Pharma US IncXtandi | $34 | $182,52613 claims |
| Johnson & JohnsonXarelto | $87 | $18,09724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Tulsa
- Caleb ScheckelTulsa$159K
- Hassan KaleemTulsa$137K
- Scott ColeTulsa$20K
- Supriya KoyaTulsa$7K
- Venkata VosuriTulsa$6K
- Kevin WeibelTulsa$5K
- Ali MoussaTulsa$5K
- Paul El TombTulsa$4K
- Muhammad JanjuaTulsa$4K
- Jennifer TrottmanTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.